$2.07 Billion is the total value of Camber Capital Management LP's 48 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GHDX | GENOMIC HEALTH INC | $63,652,000 | +4.5% | 2,458,100 | 0.0% | 3.08% | -13.7% | |
| OFIX | ORTHOFIX INTL N V | $63,600,000 | +2.1% | 1,500,000 | 0.0% | 3.07% | -15.7% | |
| SEM | SELECT MEDICAL HOLDINGS CORP | $60,600,000 | -8.0% | 5,575,000 | 0.0% | 2.93% | -24.0% | |
| LIVN | LIVANOVA PLC | $60,276,000 | -6.9% | 1,200,000 | 0.0% | 2.91% | -23.2% | |
| UAM | UNIVERSAL AMERICAN CORPORATION | $44,533,000 | +6.2% | 5,875,000 | 0.0% | 2.15% | -12.4% | |
| NVTA | INVITAE CORP | $20,298,000 | -27.8% | 2,746,622 | 0.0% | 0.98% | -40.4% | |
| SQNM | SEQUENOM INC | $15,830,000 | -35.2% | 17,325,000 | 0.0% | 0.76% | -46.5% | |
| AMAG | AMAG PHARMACEUTICALS | $14,352,000 | +2.2% | 600,000 | 0.0% | 0.69% | -15.6% | |
| PLX | PROTALIX BIO THERAPEUTICS, INC | $8,496,000 | -23.9% | 13,275,000 | 0.0% | 0.41% | -37.1% | |
| DRRX | DURECT CORP COM | $7,320,000 | -9.6% | 6,000,000 | 0.0% | 0.35% | -25.3% | |
| BIOL | BIOLASE INC | $6,239,000 | -10.7% | 5,332,394 | 0.0% | 0.30% | -26.2% | |
| PROTALIX BIO THERAPEUTICS, INCnote 4.500% 9/1 | $6,113,000 | +1.9% | 9,000,000 | 0.0% | 0.30% | -16.0% | ||
| GNMK | GENMARK DIAGNOSTICS | $5,647,000 | +65.1% | 649,097 | 0.0% | 0.27% | +36.5% | |
| CATB | CATABASIS PHARMACEUTICALS INC | $3,700,000 | -26.6% | 1,000,000 | 0.0% | 0.18% | -39.3% | |
| TARGACEPT INCnote | $1,685,000 | 0.0% | 1,684,799 | 0.0% | 0.08% | -18.2% | ||
| EPRSQ | EPIRUS BIOPHARMACEUTICALS | $835,000 | -83.2% | 1,847,500 | 0.0% | 0.04% | -86.3% | |
| BIOLASE INCcall | $4,000 | -81.8% | 1,841,173 | 0.0% | 0.00% | -100.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.